VA-CTA
23.5.2019 22:02:10 CEST | Business Wire | Press release
The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019 . Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China.
Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018.
“Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.”
Throughout Asia and beyond, technology is improving the transportation experience, making roads safer, enabling greater accessibility, creating job opportunities and allowing for greater productivity. CES Asia 2019 will feature the latest in transportation technology, doubling its footprint on the show floor and introducing a new hall with the latest concept cars and connected vehicles, from autonomous level 4 and level 5 to all-electric.
Mr. Owsianski joins top executives from Huawei and Hyundai as confirmed CES Asia keynote speakers. Additional industry thought leaders will be added to the keynote stage in the coming weeks. All CES Asia keynotes will take place at the Kerry Hotel in Shanghai Ballrooms 2-3.
CES Asia 2019 marks the fifth anniversary of one of Asia’s fastest growing tech events. CES Asia is the only event in Asia that brings together the entire tech ecosystem to build brands, forge partnerships and celebrate the best in consumer tech in Asia. The show will focus on the latest innovation in transportation tech, AI, 5G and startups from around the world, featuring more than 550 exhibiting companies, including more than 115 startups. Visit CESAsia.com for more information or to register.
WeChat registration for CES Asia 2019 is now available. Follow us on WeChat (ID: CESAsia_II) to register.
Note to Editors:
High-definition video b-roll is available for easy download on CESbroll.com . Visit the CES Asia photo gallery for the latest pictures from CES Asia 2018. Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351.
About CES Asia:
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers and international media. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About International CES (Shanghai) Exhibition Co. Ltd. and CTA:
International CES (Shanghai) Exhibition Co. Ltd. is a wholly foreign-owned enterprise by the Consumer Technology Association (CTA), a trade association representing the $398 billion U.S. consumer technology industry, which supports more than 18 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Taken independent in July 2016, Shanghai Intex Exhibition (Co., Ltd.) was originally founded in 1995 as the pioneering exhibition organizing business of Intex Shanghai, the first joint venture venue management business in Shanghai. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibitions, giving it the perfect combination of domestic and international resources. Over the last 20 years, Shanghai Intex has organized more than 100 tradeshows and over 1000 conferences, with a sum total show space in excess of 2 million square meters. Shanghai Intex runs a number of internationally renowned exhibitions covering the music industry, healthcare, lifestyle, advanced manufacturing, public transportation, floriculture, consumer electronics, technology and more.
UPCOMING EVENTS
-
CES
Asia 2019
June 11-13 – Shanghai, China -
CEO
Summit
June 23-26 – Prague, Czech Republic -
Technology
& Standards Fall Forum
September 23 – Los Angeles, CA -
CES
Unveiled in Paris
October 22 – Paris, France -
CES
Unveiled in Amsterdam
October 24 – Amsterdam, Netherlands -
CES
2020
January 7-10, 2020 – Las Vegas, NV
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005746/en/
Contact:
Teresa Hsu 703-907-5259 tshu@CTA.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom